Barish Ozdamar's practice focuses on intellectual property litigation and patent prosecution matters in the pharmaceutical, biotechnology and medical device industries. Dr. Ozdamar has counseled and assisted in matters before District Courts, the Patent Trial and Appeal Board, and in arbitration. He has extensive experience representing life science clients in Biologics and Hatch-Waxman litigation, as well as inter partes review proceedings across a range of subject matters, including antibodies, small molecules, diagnostics, genomic analysis, and sequencing technologies.

Dr. Ozdamar also has extensive experience in patent portfolio management, FTO analysis, patentability assessment, due diligence, and pre-suit investigation in life sciences matters.

Prior to joining the firm, Dr. Ozdamar was a Post-Doctoral Fellow at Cornell University Weill Medical College, where he examined the role of cholesterol metabolism in atherosclerosis and stroke. During his graduate tenure at the University of Toronto, Dr. Ozdamar's research focused on cancer biology and molecular pathways regulating tumor metastasis. He has also been the recipient of Post-Doctoral Fellowships from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. Dr. Ozdamar's publication record includes four authorships in the journal Science.


  • Obtained a favorable pre-trial result for our client, a large medical device company, in connection with a gene expression platform.
  • Successful District Court representation of a leading medical diagnostic company in a matter relating to fetal genetic testing.
  • Desired outcome for multi-national pharmaceutical client faced with an infringement suit relating to antibody and screening technologies.
  • Represented and obtained a favorable pre-trial outcome for a large biotechnology company challenged by multiple generic biologic entrants against an antibody product.
  • Successful representation of a large pharmaceutical client in an ANDA litigation relating to a small-molecule anti-cancer compound.
  • Desired outcome for a large pharmaceutical client in Swiss arbitration proceedings relating to genetic screening technologies.


  • Canadian Institutes of Health Research Post-Doctoral Fellowship
  • Heart and Stroke Foundation of Canada Post-Doctoral Fellowship
  • Canadian Institutes of Health Research Doctoral Award

Insights & News


  • Education

    • JD, Fordham University School of Law, 2011

    • Post-Doctoral Fellow, Biochemistry, Cornell University Weill Graduate School of Medical Sciences, 2007

    • Post-Doctoral Fellow, Cell Biology, 2006

      The Hospital for Sick Children, Toronto, Canada
    • PhD, Medical Genetics, University of Toronto, 2005

      Samuel Lunenfeld Research Institute, Mt. Sinai Hospital
    • BSc (Hons), York University, 1998

  • Admissions

    • New York

    • US Patent and Trademark Office

  • Languages

    • French

    • Turkish